Dr. Maurits S. Boon appointed Nyxoah's Chief Medical Officer

Nyxoah, a medical technology company specializing in innovative solutions for Obstructive Sleep Apnea (OSA), has appointed Dr. Maurits S. Boon, MD, as its Chief Medical Officer. Dr. Boon, a dual board-certified surgeon in otolaryngology and sleep medicine, brings a wealth of experience from Thomas Jefferson University, where he will continue part-time as a professor and Vice Chairman, Education.

Dr. Boon is renowned for his expertise in hypoglossal nerve stimulation therapy (HGNS) and has been instrumental in pioneering its use. His appointment comes at a crucial time for Nyxoah as they aim to make a significant impact on OSA patients' lives with their Genio system, a leadless and battery-free hypoglossal neurostimulation therapy.

Expressing his enthusiasm for joining Nyxoah, Dr. Boon highlighted the potential of bilateral hypoglossal nerve stimulation with Genio and his eagerness to work with the talented team to improve the lives of OSA patients. Nyxoah's CEO, Olivier Taelman, praised Dr. Boon's expertise and emphasized the pivotal role he will play as the company prepares to enter the U.S. market.

Nyxoah's Genio system, designed to treat OSA, has been CE marked since 2019 and is currently an investigational device in the United States. The company's vision is to provide OSA patients with restful nights and enable them to live life to the fullest.

In conclusion, Dr. Boon's appointment as Chief Medical Officer signifies Nyxoah's commitment to advancing OSA treatment and underscores the company's mission to simplify sleep for patients worldwide.